Stuart Naylor, who serves as Chief Development Officer of MeiraGTx Holdings PLC (NASDAQ:MGTX), completed a sale of 27,661 ordinary shares on April 7, 2026, generating proceeds of $258,906. The shares were sold at a weighted average price of $9.36, with individual sale prices ranging between $9.11 and $9.52.
The disposition took place while MeiraGTx shares were trading close to their 52-week high of $9.88, after the stock recorded an 81% gain over the past year. Following the April 7 transaction, Naylor directly holds 668,505 ordinary shares in the company.
Company filings indicate the sale was executed under a pre-arranged Rule 10b5-1 trading plan that Naylor adopted on December 9, 2025. The use of a 10b5-1 plan is documented in the filing and denotes pre-set parameters that governed the transaction.
Independent analysis noted in market commentary suggests the shares may still be slightly undervalued at the current trading levels. Specifically, InvestingPro analysis states that MeiraGTx appears slightly undervalued and references 11 additional ProTips available to subscribers, which include assessments of the company’s financial condition and market positioning.
Separately, MeiraGTx has been the subject of multiple company and analyst developments that have attracted attention from investors. The firm reported that its AAV2-hAQP1 gene therapy candidate received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of xerostomia. That regulatory milestone has been cited by some analysts as a key factor in revisiting valuations and potential commercial prospects.
Following the FDA announcement and the company’s fourth-quarter 2025 results, several brokerages adjusted their price targets and recommendations. BofA Securities raised its price target for MeiraGTx to $16, citing the FDA designation and the fourth-quarter results as pivotal. Piper Sandler adjusted its price target to $26 while maintaining an Overweight rating. Raymond James revised its target to $27 and retained a Strong Buy rating, while noting a change in launch expectations for the xerostomia gene therapy program.
MeiraGTx also entered into an exclusive licensing agreement with ZipBio focused on novel gene therapy approaches for Geographic Atrophy, an ophthalmic condition. Under the deal, MeiraGTx obtained exclusive rights to ZipBio’s therapies that target the complement pathway. The agreement includes upfront payments to ZipBio and carries the potential for additional milestone and royalty payments, according to company disclosures. The collaboration pairs MeiraGTx’s experience in genetic medicines with ZipBio’s AI-designed protein therapeutics.
Collectively, the insider sale, regulatory designation, analyst updates, and the licensing arrangement have kept MeiraGTx in view among investors and market commentators. The filings and analyst notes cited above form the basis for market discussion around the stock’s valuation and future prospects.